<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nandakumar K N</style></author><author><style face="normal" font="default" size="100%">Mohanraj Nehru</style></author><author><style face="normal" font="default" size="100%">Prasanth Subramanian</style></author><author><style face="normal" font="default" size="100%">Bhuvaneshwaran Mothiswaran</style></author><author><style face="normal" font="default" size="100%">Vishagan S S</style></author><author><style face="normal" font="default" size="100%">Satishkumar Rajappan Chandra</style></author><author><style face="normal" font="default" size="100%">Venkataraman Prabhu</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Potential Molecular level Impact of Cresvin beta on Type 2 Diabetes Mellitus: A Randomized Controlled Clinical Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">anti-diabetic efficacy</style></keyword><keyword><style  face="normal" font="default" size="100%">Ayurveda</style></keyword><keyword><style  face="normal" font="default" size="100%">Cresvin beta</style></keyword><keyword><style  face="normal" font="default" size="100%">Metformin</style></keyword><keyword><style  face="normal" font="default" size="100%">Sirtuin 1</style></keyword><keyword><style  face="normal" font="default" size="100%">Type 2 diabetes mellitus</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">1297-1304</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with an increasing prevalence rate over the past few decades. Despite the availability of medications to prevent and reduce disease severity, T2DM prevalence and incidence continue to rise annually. Understanding genetic heritage's impact on therapeutic responses is improving, with pharmacogenetics being used to better comprehend the therapeutic variability of T2DM. This study aims to compare the effects of metformin and Cresvin beta capsules containing Pterocarpus marsupium, Withania somnifera, Salacia reticulata, Gymnema Sylvestre, Curcuma longa, Vitis vinifera and Piper nigrum (Black pepper extract) on diabetic and immune-related gene expression in T2DM patients. &lt;strong&gt;Methods:&lt;/strong&gt; Sixty patients were divided into two groups: metformintreated (group A, n=30) and Cresvin beta -treated (group B, n=30). Anthropometric, biochemical, and hematological parameters were measured at baseline and after 3 months of treatment. Gene expression levels were analyzed using quantitative real-time polymerase chain from DNA extracted from whole blood samples.&lt;strong&gt; Results:&lt;/strong&gt; After 3 months, metformin significantly reduced fasting blood sugar (FBS), postprandial blood sugar (PPBS), and HbA1c levels (p&amp;lt;0.001). Cresvin beta also significantly reduced FBS (p&amp;lt;0.01), PPBS (p&amp;lt;0.001), and HbA1c (p&amp;lt;0.001). Gene expression analysis showed significant changes in SIRT1, AKT, SLC2A4, IL-6, and TNF-α in both groups. &lt;strong&gt;Conclusion: &lt;/strong&gt;The study demonstrated that Cresvin beta reduced glycemic levels and improved SIRT1, Pi3k, Akt, and SLC2A4 gene expression while decreasing IL-6 and TNF-α cytokine gene expression in T2DM patients.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">1297</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Nandakumar K N&lt;sup&gt;1&lt;/sup&gt;, Mohanraj Nehru&lt;sup&gt;1&lt;/sup&gt;, Prasanth Subramanian&lt;sup&gt;1&lt;/sup&gt;, Bhuvaneshwaran Mothiswaran&lt;sup&gt;2&lt;/sup&gt;, Vishagan S S&lt;sup&gt;3&lt;/sup&gt;, Satishkumar Rajappan Chandra&lt;sup&gt;2&lt;/sup&gt;, Venkataraman Prabhu&lt;sup&gt;1,*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Medical Research, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Chennai, Tamilnadu, INDIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Clinical Trial and Research Unit, Interdisciplinary Institute of Indian System of Medicine, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Chennai, Tamilnadu, INDIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Director of Apex Laboratories Pvt Ltd, Chennai, Tamilnadu, INDIA.&lt;/p&gt;
</style></auth-address></record></records></xml>